Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales).

Education

Education across our Therapeutic Areas

Diabetes

Dyslipidaemia

Neurology

Oncology

Rare Blood Disorders

Rare Diseases

Thrombosis

Vaccines

Latest Content

Educational and Training materials supporting your continuing professional development

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

Vaccines Training

Diabetes Podcast Series | Toujeo ® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL)

What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes | Toujeo ® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL)

RCT Evidence on Time-In-Range in Type 1 Diabetes | Toujeo ® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL)

Practicalities of Supporting the Teenager With Type 2 Diabetes | Toujeo ® (insulin glargine 300 Units/mL)

The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS | Praluent® (alirocumab)

Strengthening the Interface Between Primary and Secondary Care | Praluent® (alirocumab)

Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)

What More Could Be Done for the High-Risk CV Patient? | Praluent® (alirocumab)

What's the Future of Secondary Care Lipid Services? | Praluent® (alirocumab)

Managing Residual Risk in the Post Acute ACS Patient | Praluent® (alirocumab)

New Approaches and Innovation in Lipid Services – Strengthening the Relationship between Primary and Secondary Care | Praluent® (alirocumab)

Enhance your experience by signing up to Campus Pro

Personalised content and resources, tailored to your specialty and areas of interest
Access additional content related to Sanofi medicines
Register for dedicated Sanofi organised promotional events
Access to CPD accredited learning modules

Register for free

Our Products

ADMELOG
insulin lispro

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2302443 (v1.0)
Date of preparation: June 2023

ALDURAZYME
laronidase

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200954 (v3.0)
Date of preparation: October 2023

AUBAGIO
teriflunomide

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200676 (v4.0)
Date of preparation: April 2023

AVAXIM® Junior

Prescribing Information UK

MAT-XU-2301296 (v2.0)
Date of preparation: August 2023

Prescribing Information UK

MAT-XU-2301117 (v1.0)
Date of preparation: April 2023

Cablivi
caplacizumab

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105168 (v6.0)
Date of preparation: October 2023

CERDELGA
eliglustat 84mg

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204064 (v3.0)
Date of preparation: November 2023

CEREZYME
imiglucerase

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204065 (v2.0)
Date of preparation: January 2023

Clexane
enoxaparin

Prescribing Information UK

MAT-XU-2204397 (v2.0)
Date of preparation: May 2023

Fabrazyme
agalsidase beta

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105812 (v4.0)
Date of preparation: May 2023

LANTUS
insulin glargine

Prescribing Information GB
Prescribing Information NI

MAT-XU-2201444 (v3.0)
Date of preparation: January 2023

LEMTRADA
Alemtuzumab

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200680 (v2.0)
Date of preparation: August 2022

Menquadfi^TM

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301129 (v1.0)
Date of preparation: May 2023

MYOZYME
alglucosidase alfa

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105179 (v3.0)
Date of preparation: February 2023

NEXVIADYME
avalglucosidase alfa

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2203480 (v4.0)
Date of preparation: June 2023

PRALUENT
alirocumab

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204604 (v2.0)
Date of preparation: March 2023

Prescribing Information UK

MAT-XU-2301127 (v1.0)
Date of preparation: May 2023

Prescribing Information UK

MAT-XU-2301125 (v2.0)
Date of preparation: June 2023

Prescribing Information UK

MAT-XU-2301123 (v1.0)
Date of preparation: May 2023

REZUROCK
belumosudil tablets

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2202695 (v3.0)
Date of preparation: June 2023

SARCLISA
isatuximab

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2202578 (v2.0)
Date of preparation: August 2023

STAMARiL^®

Prescribing Information UK

MAT-XU-2301130 (v1.0)
Date of preparation: May 2023

Supemtek^®

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301126 (v1.0)
Date of preparation: May 2023

TOUJEO
insulin glargine

Prescribing Information GB
Prescribing Information NI

MAT-XU-2302426 (v6.0)
Date of Preparation: October 2023

TRURAPI
insulin aspart

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2205461 (v7.0)
Date of preparation: June 2023

TYPHIM Vi^®

Prescribing Information UK

MAT-XU-2301128 (v1.0)
Date of preparation: May 2023

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301124 (v1.0)
Date of preparation: May 2023

▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.

MAT-XU-2302082 (v2.0)
Date of preparation: May 2023

YOU ARE NOW LEAVING THE SANOFI CAMPUS UK WEBSITE

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

Continue

Welcome to Sanofi Campus UK

This site is intended for UK healthcare professionals only and contains information on Sanofi UK’s medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales).

MAT-XU-2300297 (v2.0)
Date of Preparation: June 2023